| __timestamp | Neurocrine Biosciences, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 18516000 |
| Thursday, January 1, 2015 | 33800000 | 34140000 |
| Friday, January 1, 2016 | 35900000 | 51872000 |
| Sunday, January 1, 2017 | 1254000 | 71772000 |
| Monday, January 1, 2018 | 4889000 | 97501000 |
| Tuesday, January 1, 2019 | 7400000 | 118590000 |
| Wednesday, January 1, 2020 | 10100000 | 169802000 |
| Friday, January 1, 2021 | 14300000 | 7491000 |
| Saturday, January 1, 2022 | 23200000 | 8799000 |
| Sunday, January 1, 2023 | 39700000 | 253598000 |
| Monday, January 1, 2024 | 34000000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and Xencor, Inc. from 2014 to 2023. Neurocrine's cost of revenue has seen a steady increase, peaking at approximately $39.7 million in 2023, a significant rise from $1.25 million in 2017. In contrast, Xencor's cost of revenue fluctuated more dramatically, reaching a high of $253.6 million in 2023, a stark increase from $7.49 million in 2021. This disparity highlights Xencor's aggressive expansion strategy, while Neurocrine maintains a more controlled growth. Understanding these trends provides valuable insights into each company's operational strategies and market positioning. As the biotech industry continues to evolve, monitoring these financial metrics will be crucial for investors and stakeholders alike.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Geron Corporation
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Insmed Incorporated and Xencor, Inc.
Cost of Revenue: Key Insights for BioMarin Pharmaceutical Inc. and Xencor, Inc.
Analyzing Cost of Revenue: Iovance Biotherapeutics, Inc. and Xencor, Inc.
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.